drugset
drugset / Trial / NCT06450106

Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy

NCT06450106 ↗

Phase 1 Recruiting 18 enrolled SURGE Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy

Timeline

Start
2025-05-08
Primary completion
2026-09
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject STM-416p Unknown — —

Indications

prostate cancer